Guggenheim Bullish on Abivax (ABVX) Ahead of Key Obefazimod Data Readout

On December 15, ABIVAX reported its fiscal results for Q3 2025. The institution generated $2.40 cardinal successful revenue, surpassing Street estimates by $1.06 million. However, determination was a nonaccomplishment per stock that totaled $1.68 successful the quarter. The nett nonaccomplishment for the 9 months widened to €254.1 million, up from €136.9 cardinal successful 2024 ($297.94 cardinal and $160.52 cardinal respectively).  The company’s fiscal enactment reflects an intensified absorption connected its pb candidate, obefazimod, a first-in-class oral miR-124 enhancer.

R&D expenses roseate to €133.4 million, driven by the progression of the ABTECT Phase 3 programme successful ulcerative colitis/UC and the ENHANCE-CD Phase 2b proceedings successful Crohn’s disease. ABIVAX is preparing for respective large milestones successful 2026. Topline results from the ABTECT Maintenance Trial are expected successful the 2nd 4th of 2026, which volition service arsenic the last objective instauration for a planned NDA submission to the FDA successful the 2nd fractional of that year.

ABIVAX Société Anonyme (NASDAQ:ABVX) is simply a clinical-stage biotechnology institution that develops therapeutics that harness the body’s earthy regulatory mechanisms to stabilize the immune effect successful patients with chronic inflammatory diseases.

While we admit the imaginable of ABVX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.